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It is now clear that immune responses are regulated by cells and antibodies that are 
specific  for  idiotypie  determinants  as  well  as  by  cells  and  antibodies  specific  for 
conventional antigenic  determinants  (1-4).  Indeed,  idiotype (Id)l-based  regulatory 
systems have the capacity to favor the use of certain clones of lymphocytes, quite 
independently  of the  capacity  of those  clones  to  bind  antigen  (5,  6).  Id-based 
regulatory systems  also  offer the  possibility  of extended chains  of complementary 
members (i.e., Id, anti-Id, anti-[anti-Id], etc.) and might serve to interlink clones that 
express  similar  Id  even  if they share  essentially  no  antigen-binding  activity.  The 
implications of such regulatory networks have been pointed out by Jerne and others 
(7-9). 
Efforts to explore the regulatory consequences of immunity to a given Id, anti-Id, 
or anti-(anti-Id)  have recently been initiated. These studies have demonstrated that 
such immunity can markedly influence which members of the repertoire of antibodies 
specific for a given antigen are actually used (10-12). 
We and our colleagues have studied an immune system particularly well suited to 
the examination of Id-based regulation. The system involves the response of BALB/ 
c mice to bacterial levan (BL), a 8(2---*6) fructosan with fl(2---*  1) branch points. The 
antibodies produced in response to BL consist of two broad families of molecules (13). 
One group of antibodies is specific for fl(2---~  1) linkages and reacts with inulin (In), a 
fi(2---*l)  fructosan, as well as with BL. Most of these anti-fi(2---*l) antibodies express 
cross-reactive idiotypes (the In-IdX) found on a series of In-binding myeloma proteins 
(14). The IgG anti-/~(2---*l)  antibodies made in BALB/e mice express great homoge- 
neity (15,  16). They are essentially all IgG3 molecules and their isoelectric focusing 
(IEF)  patterns  are  identical  to  that  of J606,  a  BALB/c IgG3  In-binding myeloma 
protein.  2 The expressed anti-In repertoire is controlled by St-l, an autosomal gene not 
linked to the Igh-C gene complex (16), and also by Igh genes (14, 16). 
* Supported in part by grant IM-275 from the American Cancer Society. 
1  Abbreviations used in this paper: Abl Id, idiotype of Abl; Abl, A48 myeloma protein; Ab2, anti-A48 
antibody; Ab3, anti-(anti-A48) antibody; Ab4, anti-(anti-[anti-A48]) antibody; BL, bacterial levan; CFA, 
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The  other  major  family of anti-BL  antibodies  bind  fl(2---~6)  fructosan  linkages. 
These antibodies are more heterogeneous by IEF analysis, although still comparatively 
simple  (16).  The  Id identified  on  the ~(2---~6)  fructosan-binding  myeloma proteins 
ABPC48  (A48 or Abl)  and UPC 10 are not  generally detected  in the serum of mice 
immunized  with  BL  (14).  However,  anti-BL  molecules  expressing  the  idiotypic 
determinant(s) of Abl (Abl Id) are part of the repertoire. They are found in the anti- 
BL antibody response of congenitally athymic (nu/nu)  BALB/c mice pretreated with 
anti-In-IdX antibody, although not in the response of "normal" nu/nu mice (17). 
In the present experiments, we have immunized BALB/c mice with Abl, BALB/c 
anti-A48  (Ab2), and BALB/c anti-(anti-A48)  (Ab3),  and have examined the effect of 
such  immunity on  the  total anti-BL response and on the  expression of Ahl  in  this 
response. Interestingly, mice immunized with Ab2 that have produced Ab3 express a 
substantial amount of Abl in their anti-BL response. In contrast, mice producing Ab2 
and  anti-(anti-[anti-A48])  (Ab4)  show  a  generalized  inhibition  of the  total  anti-BL 
response. 
Strikingly,  Ab3 expresses idiotypic cross-reactivity with  Aba  in  that  Ab4 binds to 
Abl, and Aba inhibits  the binding of radiolabeled Ab3 to Ab,. Although  this cross- 
reaction  is of relatively low affinity, it  is a  feature of 60-70% of the Ab3 molecules 
detected in this assay. This implies that the Id-anti-Id chain is not unidirectional and 
strongly suggests  that  immunization  with  Ab2 causes  the  production  of "Abl-like" 
molecules (Ab3) because it binds to Abl-like idiotypic determinants on B lymphocytes. 
Finally, we have encountered an immunization procedure in which administration 
of Ab~  to BALB/c mice leads to the production of Ab3.  These Ab3-producing mice 
resemble Ab2-immunized mice in  that,  upon  immunization  with  BL,  they produce 
antibodies expressing the Abl Id. This suggests that functionally important [d-anti-Id 
chains may be initiated in the course of "normal" immune responses. 
Materials and Methods 
Mice.  BALB/c AnN mice, 8-12 wk old, were used in this study. 
Antigens.  BL from Aerobacter levanicum (ATCC  1552) was obtained as previously described 
(14). 
Myeloma Proteins.  Abx and UPC10, fl(2---,6) fructosan-binding BALB/e myetoma proteins, 
and MOPC-384, a  Salmonella tranaroa lipopolysaccharide-binding BALB/c myeloma protein, 
were the gifts of Dr. Michael Potter, National Cancer Institute, National Institutes of Health, 
Bethesda,  Md. Aba and MOPC-384 are IgA, K-proteins; UPC10 is an IgG2a, K-protein. 
Preparation ofAnti-ld Antisera.  Ab2 antisera were prepared in A/He mice by immunization 
with Ab~ myeloma protein and in BALB/c mice by immunization with an AbI-keyhole limpet 
hemocyanin (KLH) conjugate. Ab3 antiserum was prepared in BALB/c mice by immunization 
with a KLH conjugate of affinity chromatography-purified BALB/c Ab2 Id antibody. Similarly, 
Ab4 antiserum was prepared by immunization of BALB/c mice with  a  KLH conjugate of 
purified BALB/c Aba antibody. Purification of antibodies on Sepharose 4B-anti-Id columns, 
coupling of affinity chromatography-purified antibodies to KLH, and immunization schedules 
are as previously described  (18). 
Preparation of Coupled Sheep Erythrocytes (SRBC).  An O-steroyl derivative of BL was prepared 
according to the technique of HS.mmerling  and Westphal  (19) and then coated to SRBC as 
previously described  (14). SRBC  were  coated with  myeloma proteins  and  various affinity 
chromatography-purified antibodies by the chromic chloride method, using a concentration of 
0.6-1.0 mg/ml of appropriate protein. 
Determination of Hemagglutinin (HA) Titers.  HA titers of antibodies specific for BL and for Id 
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or affinity chromatography-purified antibodies. The  titer recorded  is  1/log2  of the  highest 
dilution of antisera giving agglutination. 
Determination of Serum Id.  An HA-inhibition (HI) method described previously (13, 14) was 
used to  test  sera for the presence of Id. The Abl Id was  studied by using both A/He and 
BALB/c Ab2 antisera and Abrcoated SRBC. BALB/c Ab3 antisera and affinity chromatog- 
raphy-purified Ab2 antibody-coated SRBC were used to detect Id of Abz antibodies. BALB/c 
Ab4 antisera and affinity chromatography-purified Ab3 antibody-coated SRBC were used to 
detect Id of Aba antibodies. 
Radioimmunoassay (RIA).  Purified Aba antibodies and Abl myeloma protein were tritiated 
according to the method of Wilder et al.  (20). Aba antibodies were labeled with izsI by the 
chloramine T  method  (21). The  ability of BL  to  bind  to  aH-Abl  myeloma protein  was 
determined in mierotiter plates that had been incubated for  18 h with 50 pg BL, followed  by 
three washings with saline. The plates were incubated for 1 h with 50% fetal calf serum (FCS) 
and, after three washings, incubated for 3 h with SH-Abl (10,000 cpm/50 #l). The ability of all  - 
Abl, aH-Aba, and 125I-Aba  to bind Ab2 antibodies or Ab4 immunoglobulin  (Ig) was determined 
with the use of microplates that had been incubated with various amounts of purified Ab2 
antibodies or  with  the  Ig  fraction of Ab4  antiserum for  18  h  at  4°C.  After washing and 
incubation with 50% FCS as described above, the plates were incubated for 3 h with 3H-Abl, 
aH-Aba  (~5,000 cpm/50 #1), or  ~2~I-Aba (39,000  cpm/50 bd). To determine the capacity of 
various proteins or sera to inhibit the binding of radiolabeled Ab3 antibodies or of 3H-Abl to 
Ab2 or Ab4, plates coated with Ab2 antibodies or with Aba Ig were incubated for at least 3 h 
with various dilutions of inhibitor and washed before the addition of radiolabeled antibodies 
(22). Radioactivity on plates was measured in a liquid-scintillation  spectrometer. 
Plaque-forming Cell (PFC) Assay.  The number of PFC-secreting antibodies specific  for  BL 
was determined according to a  previously described technique (13). PFC secreting anti-BL 
antibodies carrying the Abl Id were enumerated by the addition of BALB/c (1:300) or A/He 
(1:150) anti-A48 Id antisera to agarose,  The number of PFC obtained in the presence of these 
sera was subtracted from that obtained if no inhibitory serum was present to give the number 
of Aba Id  + anti-BL PFC. 
Results 
Characterization  of Id.  A series of anti-Id antibodies mimicking an Id-anti-Id chain, 
or pathway, comprising Ab2, Ab3, and Ab4 antibodies was induced by immunization 
of syngeneic mice with KLH conjugates ofAbx, Ab2, and Abz antibodies, respectively. 
The  presence of these  anti-Id antibodies was  determined by  HA  and  RIA assays. 
Thus, Ab2 antiserum agglutinated both  AbrSRBC  and Abz-SRBC  (Table I).  The 
Abx-SRBC  agglutinating activity  of  Ab2  antiserum  was  completely  removed  by 
TABLE  I 
HA Titers of Aba, Aba, and Ab4 Antisera 
HA titers* on SRBC coated with 
Sera  Abl  Ab2  Aba 
Unad-  Unad-  Unad- 
sorbed  Abl$  Aba  sorbed  Ab2  sorbed  Aba 
Nonimmune  0  ND§  ND  0  ND  0  ND 
Anti-A48-KLH (Abe)  10  0  2  0  0  9  2 
Anti-(anti-A48)-KLH (Aba)  0  0  ND  10  0  0  0 
Anti-(anti-[anti-A48])-KLH (Ab4)  3  2  0  0  0  4  0 
Rabbit anti-mouse r  >12  ND  ND  >12  ND  >12  ND 
* HA titers in logs units. 
$ Sera adsorbed with Sepharose 4B conjugated with Aba, purified Ab2, or purified Aba. 
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absorption  of the  antiserum  with  Aba-Sepharose  beads  and  largely, although  not 
completely, with Aba-Sephar0se beads. Ab3 antiserum agglutinated Ab2-SRBC. 
The  antiserum containing Ab4  antibodies agglutinated Abs-SRBC,  as expected. 
However, it also agglutinated Aba-SRBC. Interestingly, the capacity of Ab4 serum to 
agglutinate AbrSRBC was completely removed by absorption with Aba-Sepharose 
beads but only partially removed by Abl-Sepharose beads  (Table I). These results 
indicate that Ab4 can bind to Abl but suggest that this binding is of relatively low 
affinity. To study this in greater detail, we examined the binding of 125I-Ab3 by both 
Abz- and Ab4-coated microplates and compared this with the binding of aH-Abl by 
similar microplates (Table II). We observed that 12SI-Aba and aH-Aba bound to both 
Ab2 and Ab4 plates. Controls using BALB/c Ig and Aba plates indicated the specificity 
of this binding. The ratio of amount of aH-Abl bound by the Ab4 and Ab2 plates and 
the ratio of ~I-Ab3 bound by these plates were similar.  Because all Aba and Ab3 
molecules should be  specific for Ab2,  the similarity of this  ratio suggests that  the 
fraction of the Aba molecules specific for Ab4 is similar to the fraction of Abs molecules 
specific for Ab4. Furthermore, Abl can inhibit the binding of 60-70% of radiolabeled 
Ab3 to Ab4 plates. Control proteins such as MOPC-384 and UPCI0 cause little or no 
inhibition. One such inhibition experiment is illustrated in Fig. 1. Comparable results 
have been obtained in three additional experiments, using aH-Aba as well as 125I-Aba. 
The relative affinity of Ab4 for Abl can be estimated from the concentration of Abl 
required to inhibit binding of lzSI-Abs or of aH-Abt to Ab4 microplates (Table III). 
We found that 2.2 pg/ml of Abl was needed to inhibit 50% of the binding of 12SI-Aba 
to Ab4 plates, whereas only 0.006 ~g/ml of Aba was needed for comparable inhibition. 
This suggests that Ab4 binds to Aba with substantially greater affinity than it binds 
to Abl. On the other hand, a  concentration of 0.03 pg/mt of Abl was sufficient to 
inhibit 50% of the binding of 3H-Abl  to Ab4 microplates. This is consistent with a 
relative affinity of the binding of Ab4 to Abe, which is greater than that indicated by 
Aba inhibition of binding of Ab4 to Ab3 plates, although still lower than the relative 
affinity of binding of Ab4 to Aba. At this time, we cannot fully reconcile these differing 
estimates of the relative affinity of Ab4 for Abl. 
The interactions of these anti-Id antibodies were also studied by an HI assay. The 
agglutination of Abl SRBC by A/He and BALB/c Ab2 was inhibited by Abl myeloma 
protein (Table IV). The agglutination of Abrcoated SRBC by BALB/c Ab2 antibod- 
TABLE II 
Binding of Radioactive Abl and Ab3 to Plates Coated with Abz and Ab4 
Microplates coated with 
Bound ligand 
3H-Abl  ~25I_Aba 
(pill 
BALB/c Ig (10 p,g/ml)  105  1,130 ±  111 
Abs (10/~g/ml)  110 ±  8  ND* 
Ab2 (10/~g/rnl)  1,386 ±  142  22,944  ±  1,374 
Ab4 (150 p,g Ig/rnl)  524 ±  19  8,173 ±  271 
Specific binding to Ab4/specific to Ab~:  0.33  0.32 
* Not done. 
:~ Binding to Ab4 plate -  binding to control plates/binding to Ab2 plate -  binding to 
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Fro.  1_  Inhibition of binding of 3H-Abl and  ]2~I-Abs to Ab2 and  Ab4 microplates. Microplates 
were coated with Ab2 (10/Lg/ml purified antibody) and Ab4 (150 #g/ml Ig) as described in Materials 
and  Methods. Plates were preincubated with various concentrations of Abl, Aba, or MOPC-384, 
and washed, t~I-Ab3  or ZH-Ab~ were then added and binding measured.  Percent inhibition was 
calculated as follows: 
cpm bound after addition of inhibitor -  cDm bound to control plate.~ 
% inhibition =  100  1 -  -cp'--m  houn-----dwit--h  n---oi-nhibito----~---  cp---m  bound  t----~con'--tro---~  pla---~e  )" 
Control plates for aH-Aht were coated with BALB/c Ig and with Abz Ig; control plates for t25I-Aba 
were coated with BALB/c lg. The cpm bound to control plates and  to Ab2 and  Ab4 plates are 
presented in Table II. 
TABLE  III 
Inhibition of Binding of Radioactive Abl and Aba to Plates Coated with Abe and Ab4 
Microplate coated with  Ligand 
[Inhibitor]  for 50% inhibition 
Abl  Aba  MOPC-384 
Itg/ml 
Ab2 (10 #g/ml)  aH-Ahl  0.003  ND*  >100 
Ab2  ]25I-Ab~  0.007  ND  > 100 
Ab4 (150 #g Ig/ml)  aH-Ab~  0.03  ND  >100 
Ab4  l~SI-Ab3  2.2  0.006  > 100 
* Not done. 
ies was also inhibited by Ab3. On  the other hand, Aba did not inhibit the ability of A/ 
He  anti-Abx  to  agglutinate  Abl-SRBC.  These  results  indicate  that  A/He  Ab2  lacks 
idiotypic determinant(s)  borne by BALB/c  Ab2 antibodies or, as discussed  later, that 
A/He  Ab2  is  directed  to  different  idiotypic determinants  on  Abt  than  are  BALB/c 
Ab2 antibodies. 
The  agglutination  of BALB/c  Ab2-SRBC  by  Aba was  inhibited  by  BALB/c  Ab2 
and by Ab4 (Table IV). The  inhibitory ability of BALB/c  Ab2 was shared by BAB. 14 
and  C.B20 Abz antibodies  but  not by A/He  and AL/N  antibodies  (data  not shown). 956  AUTO Abn AND SILENT CLONES 
TABLE  IV 
HI Titers of Abz ld, Ab3 ld, and Ab4 ld Antisera 
Inhibitory serum 
A/He  BALB/c 
Ab2 +  A~ +  Aba + 
Abl- 
SRBC  Abl-  Ab2- 
SRBC  SRBC 
Ab4 + 
Aba- 
SRBC 
log2 U 
Nonimmune serum  0  0  0  0 
Abl (3 mg/ml)  8  8  0  1 
Anti-A48-KLH (Ab2)  0  0  8  0 
Anti-(anti-A48)-KLH (Aba)  0  8  0  7 
Anti-  (anti-  [anti-A48]-KLH) (Ab4)  0  0  6  0 
TABLE V 
Anti-BL HA Titer 
Number of  HA titer (BL-  Sera  mice  coated SRBC) 
log2 u 
Normal  2  2.5 
Aba (3 mg/ml)  --  11.0 
Anti-A48-KLH (Ab2)  5  1.8 
Anti-(anti-A48)-KLH (Aba)  9  2.1 
Anti-  (anti-[anti-A48Id])-KLH (Ab4)  3  2.3 
The agglutination of Aba-SRBC by Ab4 was inhibited  by Aba, as anticipated.  In 
addition, it was inhibited by high concentrations of Aba. This is similar to the finding 
that  relatively  high  concentrations  of Abl  are  required  to  inhibit  the  binding  of 
radiolabeled Aba to Ab4-coated plates.  Both results indicate that Ab4 recognizes Aba 
and Abl, although its affinity for Abl is lower than that for Aba. 
The Ab2, Aba, and Ab4 antisera did not react with BL to any greater extent than 
did normal serum  (Table V). The low anti-BL HA titer of these antisera and of the 
sera of normal nonimmunized BALB/c mice presumably represents the presence of 
"natural" anti-BL antibodies due to immunization with environmental antigens (22, 
23).  This  phenomenon  is  common  for  several  polysaccharide  antigens  borne  by 
saprophytic intestinal flora. 
These results indicate that through intentional immunization a set of complemen- 
tary anti-Id antibodies  can  be  produced and  that  each  differs  from  the others.  In 
particular, Aba differs from Abl in that it lacks the capacity to agglutinate BL-SRBC 
(Table V) and to bind to BL-coated plates (data not shown). Ab4 differs from Ab2 in 
that its ability to agglutinate AbI-SRBC is ineffectively removed by Abl-Sepharose 
and its ability to bind both radiolabeled Ab3 and Aba-SRBC requires high concentra- 
tions of Aba for inhibition.  Nonetheless,  this analysis indicates that  the majority of 
Aba molecules express an IdX which cross-reacts with an Id found on Abl. This result 
is quite unexpected in a  "linear" Abl-Ab.i2-Aba-Ab4 system, but is comparable to a 
previous result of Wikler et al.  (24) in a similar rabbit system. 
Immunization  with Abl  Causes  the Production of Aba.  The previous experiments dem- 
onstrate the characteristics of members of an Id-anti-Id chain induced by intentional 
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chain.  In order to determine whether the chain normally develops beyond the first 
step  after immunization  with  native Abl, we  immunized  BALB/c  mice with  Aba, 
using two different protocols, and tested for the appearance of both Ab2 and Abs. 
One group of seven mice was immunized eight times with Abl not conjugated to 
KLH. The immunization protocol consisted of an initial immunization in complete 
Freund's  adjuvant  (CFA),  followed  by one  immunization  in  incomplete  Freund's 
adjuvant  (IFA), and  then by six weekly immunizations in  saline.  These mice were 
bled weekly after the completion of the entire protocol. Each of the mice of this group 
made Ab2, which was found over an 8-wk period after completion of immunization. 
Aba was not detected in any of these mice during this period (Fig. 2). 
In five of the mice of this group, the Ab2 observed differed from the Ab2 found in 
BALB/c mice after immunization  with Abl conjugated  to KLH  (see Table I). The 
Ab2 of these five mice failed to agglutinate Aba-SRBC. In two of the seven mice, the 
sera could  agglutinate  both Abx-SRBC and  Abs-SRBC,  although  the  titers  varied 
substantially  during  the  8-wk period.  Furthermore,  these  two  mice may also  have 
produced Ab4. We suggest this because adsorption of their sera with Abl-Sepharose 
only partially removed the ability to agglutinate Abs-SRBC, whereas absorption with 
Aba-Sepharose removed it completely (Table VI). 
A  second  group consisting of four mice was  immunized twice with Aba, once in 
CFA and once in IFA. These mice expressed a  low serum titer of hemagglutinating 
Ab2 antibodies  1 wk after the completion of immunization  (Fig.  3).  By 3  wk after 
completion of immunization, three of these mice had no detectable Ab2 serum titer 
and  one mouse had  a  very low titer in  its serum. At this time, each of these mice 
displayed a significant Abs titer. By 5 wk, the Abs titer had fallen in all but one of the 
mice and was replaced by Ab2, but by 8 wk, Abs was again found in the absence of 
detectable Ab2.  Thus, mice immunized in this way with Abl show a prompt appear- 
ance of Ab2 and then show an inverse fluctuation in Ab2 and Abs levels. However, we 
have  not  examined  the  second  peak  (at  5  wk)  of Ab2  HA  activity  to  determine 
whether it represents an Ab2 or Ab4, or a mixture of Ab2 and Ab4. 
Our  data  indicate  the appearance of auto-Aba and possibly of auto-Ab4 in  mice 
immunized with Abl. This is consistent with the development of an extended chain 
of anti-Id reactions in individual animals. 
Activation of  Abl Id ÷ Anti-BL Precursors  in Mice Immune to Abe.  Normal BALB/c mice, 
as well as BALB/c mice that had been immunized with Ab2 Id antibodies, have low 
serum anti-BL HA titers and a  small number of anti-BL PFC  (Table VII). No Abt 
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FxG.  2.  HA titer ofsera of BALB/c mice immunized with Abl not conjugated to KLH, according 
to the eight-immunization protocol. HA titer with A48-SRBC (Ab]) is interpreted to represent Al:~ 
titer; HA titer with anti-A48-SRBC (Ab~-SRBC) is interpreted to represent Aba titer. 958  AUTO  Aba  AND  SILENT CLONES 
TABLE  VI 
HA  Titers of Serum from BALB/c Mice That Had Received Ezght 
Immunizat,ons  with Abl * 
Serum  HA titer 
Time after com- 
pletion of immu- 
nization 
AdsorptionS:  Abl-SRBC  Aba-SRBC 
wk 
1 
tog~u 
--  4  6 
Abl  1  4 
--  4  4 
Abt  1  3 
Aba  2  0 
MOPC-384  3  3 
* Sera  from  two  mice  that  produced  Ab~  antibody  that  agglutinated  Aba- 
SRBC were tested. 
:~ Serum (0.2 ml) was adsorbed with 0.1  ml of Sepharose 4B beads to which 
the indicated protein had been conjugated. 
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FIG.  3.  HA titer of sera of four individual BALB/c mice immunized with Abt, not conjugated to 
KLH, according to the two-immunization protocol. Anti-A48Id (Ab2 Id) titer represents HA titer 
with AbrSRBC;  anti-(anti-A48Id)  (Aba Id) HA titer represents HA titer with Ab2-SRBC.  Serum 
titers of individual mice are denoted as follows:  mouse 1-O; mouse 2-ZX; mouse 3-E]; mouse 4-~. 
TABLE  VII 
Anti-BL Response of Mice Immune to Ab~ 
Pretreatment 
Immu-  Response 
niza-  Num- 
HI Abr  BL PFC  tion  ber of 
HA (BL-  SRBC +  RIA~ Abl 
withBL,  mice  SRBC)  BALB/c  Total PFC/  Abl Id 
Ab2  spleen 
IZg/ml  % 
None  -  2  2.5+_0.7  0  <0.1  24+  11  4+5 
Ab2-KLH  -  4  3.8 ±  0.3  0  <0.1  44 +- 33  5 ±  3 
None  +  5  6.0±  1.2  0  <0.I  330±34  9+6 
Ab2-KLH  +  9  7.8 +- 3.2  1.8 ±  0.7  4.8  :l:  1.6  765 ±  433  32 ±  20 
Abl (8 immunizations)  +  6  3.3 +-  1.1  0.9 ±  1.2  <0.1  435 ±  102  18 ±  10 
Abl (2 immunizations)  +  4  10.8 ±  1.3  2.8 -t-0.5  10.3  ±  1.8  1,192  +_  180  47 ±  13 
* Mice were immunized with 10 #g BL  10 wk after completion of pretreatment. Responses were measured 
5 d after BL immunization. 
:~ Results calculated based on the capacity of various concentrations of Ab~ to inhibit binding of aH-Ab~ to 
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Id  +  antibodies  could  be detected  by either  HI, RIA, or PFC  assays in  these  mice. 
Immunization  with  BL  leads  to  the  development  of a  significant  titer  of anti-BL 
antibodies and anti-BL PFC. As we have previously shown, Abl Id  + anti-BL antibodies 
are not detected in this response (17).  BALB/c mice that had been immunized with 
Ab2-KLH developed a  vigorous response upon  immunization  with  BL, and a  sub- 
stantial  fraction of their anti-BL antibodies expressed the Abl Id. Immunized mice 
producing Ab2 (and possibly Ab4), as a  result of immunization  with Abl using the 
eight-injection protocol, developed an anti-BL response of lower magnitude than did 
normal mice immunized with  BL. They failed to express Abx Id. In contrast,  mice 
that had produced Aba as a result of immunization with Abl using the two-injection 
protocol expressed a marked increase in their total anti-BL response and developed a 
considerable  amount  of Abl  Id  ÷  anti-BL antibodies  upon  immunization  with  BL. 
Thus, in these animals, the presence of immunity to Ab2 before immunization with 
BL  was  associated  with  the  expression  of the  Abl  Id  in  the  anti-BL  response.  In 
contrast, the presence of Ab2 itself was associated with a  failure of expression of Abl 
Id and a decrease in the total anti-BL response. 
Further,  we examined  the kinetics of the response to BL of mice producing Ab2, 
Abz, and Ab4 as a result of immunization with KLH conjugates of Abl, Ab2, and Ah3, 
respectively. As noted above, Ab2 mice immunized with BL developed a  lower anti- 
BL response compared to  BL-immunized normal  BALB/c  mice.  The titer  in  such 
Ab2 mice did not approach normal levels until 20 d  after immunization  (Fig. 4). Ab3 
mice immunized with BL exhibited a total anti-BL response quite similar in amount 
to that of normal mice. Most interestingly, Ab4 mice showed a  degree of suppression 
of their  total  anti-BL response that  was  at  least  as profound  as that  of Ab2  mice. 
These results suggest that Ab2 and Ab4 express a  functional similarity and reinforce 
serologic evidence that indicates that Ab4 resembles Ab2 in that it binds Abe. 
Discussion 
Our  results  demonstrate  that  a  chain of complementary anti-Id antibodies  com- 
prising four members (Abl, Ab2, Ab3, and Ab4) can be generated by immunization of 
syngeneic mice with KLH conjugates of the immediately preceding member of the 
chain. Thus, these results formally demonstrate that in syngeneic animals an extended 
Id-anti-Id regulatory system is possible. A similar four-member chain  (Abl-Ab4) has 
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FI<3, 4.  Anti-BL HA titers of sera of BALB/c mice preimmunized with Abi KLH (A-producing 
anti-A48Id [Ab2 ld] antibodies); anti-A48-KLH (l~, producing anti-[anti-A48Id] [Ab3] antibodies); 
or  anti-(anti-A48)  [Ab3]-KLH  (I-producing  anti-[anti-(anti-A48)]  [Ab4])  antibodies.  Titers  of 
nonpreimmunized mice designated with O. All mice were immunized with  10 pg BL  10 wk after 
completion of preimmunization. Each point represents average +  SD of three mice. 960  AUTO  Ab3 AND SILENT CLONES 
been described by Wikler et al.  (24)  in allotype-matched rabbits, and three-member 
chains (Abl-Ab3) have been described previously in syngeneic mice (18) and allotype- 
matched rabbits (10). 
We observed that  immunization  with  unconjugated  Abl,  under  certain  circum- 
stances,  leads to the occurrence of auto-Ab3, as well as auto-Ab2.  Furthermore, our 
results suggest  that  such immunization  may occasionally lead  to the production  of 
auto-Ab4. These observations indicate that the chain developed by stepwise immuni- 
zation with KLH conjugates can be observed under normal conditions. Prior evidence 
that  initial  events  in  chain  formation occur has  been  obtained.  Thus,  it  has  been 
reported that the immunization with conventional antigens leads to the occurrence of 
auto-anti-Id antibodies  (25-27), auto-anti-Id PFC  (13,  28), and auto-anti-Id-binding 
cells (29-31).  Naturally occurring Id-specific T  cells (2),  as well as Id-specific T  cells 
generated  after immunization  with  Id-bearing antibodies  (30,  32),  with  Id-bearing 
antibodies coupled to syngeneic cells (31, 33), or with anti-Id antibodies (30, 34), have 
also been described. 
The presence of immunity to Abl, Ab2, or Ab~ in mice has a  significant effect on 
the amount and nature of the antibody response to BL, which is the antigen that is 
the putative initiator of the Id-anti-Id chain. Thus, in mice that have produced Ab3, 
either because of immunization with KLH-Ab2 or after responses to Abl, we observed 
that the primary response to BL contained a major fraction of antibodies that express 
the Abl Id. This Id is not detected in the response to BL of normal or nu/nu mice of 
the Igh a type, nor is it found in the response of intact BALB/c mice that have been 
pretreated with antibody to the In-IdX (35). The only previous situation in which we 
observed the appearance of measurable amounts of the Abl Id in anti-BL antibodies 
was in the response to BL of nu/nu BALB/c mice that  had previously been treated 
with  anti-In-IdX  (17).  If such  mice  are  given  T  lymphocytes  at  the  time  of BL 
immunization,  the Abl  Id is not observed in  their antibody response. This suggests 
that the expression of Abl Id is under some type of T  lymphocyte-dependent control 
and  that  the  Ab~  Id  is  probably  not  a  major  member of the  anti-BL  repertoire, 
because suppression of the anti-B(2--~ 1) component of the anti-BL response is required 
for its expression even in the absence of T  cells. 
In this context, it is interesting to consider why immunity to Ab2 should lead to the 
development of an  Abl  Id  ÷ anti-BL  response.  One  obvious possibility is  that  Ab3, 
which  is  anti-(anti-A48Id),  could  eliminate  suppressor T  lymphocytes that  express 
Ab2 (anti-A48Id) specificity. Indeed, we have shown in the MOPC-460-trinitrophenyl 
(TNP)  system that  mice immunized with Ab2  (anti-MOPC-460)  lack 460Id-specific 
suppressor T  cells, which are found in normal mice and which regulate the activation 
of  the  precursors  of  460Id ÷  anti-TNP  antibody-secreting  cells  (12).  However,  if 
elimination of suppressor T  cells specific for Abl Id (i.e.,  Ab2-bearing suppressors)  is 
the only reason that immunity to Ab2 leads to expression of Abl, one might anticipate 
that nu/nu mice immunized with  BL would express substantial Aba  Id in their anti- 
BL response. As we noted above, this is not the case. A second possibility is that Ab3 
could be regarded as consisting of the entire set of antibodies that can react with Ab2. 
Because Abz  is anti-A48Id,  Ab3 would  be expected to include  Aba.  However, mice 
immunized with Ab2-KLH, but not with BL, have no greater anti-BL serum antibody 
titer than do normal mice. Thus, Abl cannot be a very important component of Ab3. 
Nonetheless, precursors of Abl  (i.e.,  A48Id  + anti-BL)  antibody-secreting cells appear CONSTANTIN A.  BONA, ELLEN HEBER-KATZ, AND WILLIAM E.  PAUL  96l 
to have been primed by immunization with Ab2, because BL immunization leads to 
their activation and to the appearance ofAb~ Id in the anti-BL response of Ab2-KLH 
primed mice, and of those Abl-immunized mice that produced Aba. It seems likely to 
us that both of these mechanisms contribute to the regulation of the Abl Id  + anti-BL 
response in mice that have produced Ab3. 
One of the most interesting results to emerge from these studies and those of Wikler 
et al. (24)  is the apparent asymmetry of the chain of anti-Id. Thus, we observed that 
Ab, resembles Abe  in  that  both  bind  to Abl  and  to Abz,  and  that  both  lead  to a 
suppression of anti-BL antibody response. Although  Ab4 and Ab2 are not  identical, 
because their affinities for Abl are different, it is particularly important to note that 
the majority of the Ab4 molecules tested in our assays bind Abl. This was shown by 
the fact the Abl inhibited  the binding of >60%  of radioactive Ab3 by an Ab4 plate 
and  by the capacity of high  concentrations  of Abl  to  inhibit  hemagglutination  of 
Ab3-SRBC by Ab4.  In contrast, Abs and Abl differ in that Ab8 fails to recognize BL, 
whereas Abl is a  BL-binding myeloma protein. In the studies of Wikler et al. (24), a 
four-member chain was initiated with antibody to the polysaccharide from Micrococcus 
lysodeikticus. In these experiments, Ab4 and Ab2 both bound to Abl, but Aba failed to 
bind to M. lysodeikticus polysaccharide antigen. 
It is possible that the chain is only seemingly asymmetrical and the appearance of 
asymmetry is due to a  relatively low affinity of Abl for the polysaccharide antigens 
(BL  and  M.  lysodeikticus  polysaccharide)  used  in  these  systems.  If Aba  were  cross 
reactive with Abl but had an energy of binding which was 1 or 2 kcal lower than Abe, 
it might fail to bind antigen under the conditions used. In contrast, it is likely that the 
Ab2-Abl interactions, representing antibody-protein antigen interactions, are of rela- 
tively high affinity, and that the binding by cross-reactive Ab4 would be detectable 
even if the energy of interaction of Ab4 for Abl was considerably less than that of Ab2 
for Abl.  In  fact, there are three reported  instances of Ab3 displaying some Abl-like 
antigen-binding  activity.  These are in  systems in  which  the  initiating  antigens  are 
insulin-binding receptor (36), retinol-binding receptor (36), and tobacco mosaic virus 
capsid protein (37). However, our observation that the majority of Ab4 molecules bind 
Ab~ suggests that this is an important feature of Id-anti-Id chains. 
Consequently, we wish to suggest an explanation for the observed lack of symmetry 
in this chain of anti-Id which represents a distinctive view of the Id-anti-Id regulatory 
system. In considering this proposal, we first wish to outline what we believe to be a 
major difficulty in certain of the network concepts. In the most simplified and extreme 
case, one imagines a physiologic network to be initiated by the antibody produced in 
response to antigenic determinants.  Such antigenic determinants, in accordance with 
the Jerne nomenclature, are termed epitopes (7). Anti-epitope antibodies (Abl) express 
Id that are currently recognized to actually consist of a  series of distinctive determi- 
nants located on different portions of the variable region. These individual  idiotypic 
determinants have been designated idiotopes. Because each Abl may express at least 
two and probably several idiotopes  (38),  there should be at  least two and probably 
several  Ab2  generated  in  response  to  each  Abl  (39).  Similarly,  each  Abz  should 
stimulate the appearance of several Ab3 and each of these, in turn, should stimulate 
the  appearance  of several  Ab4.  This  would  suggest  that  the  number  of distinct 
molecules in the set of Ab2, Ab3,  ...  Abn antibodies must be very much larger than 
the  set  of distinct  Abi  antibodies,  and  that  the  bulk  of the  antibody  repertoire  is 962  AUTO Ab3 AND SILENT CLONES 
devoted to recognition of idiotopes. This concentration on  idiotopes might  be more 
illusory  than  real  if most  anti-idiotope  antibodies  also  recognized  some  epitope, 
presumably because of a structural similarity between the particular idiotope and the 
particular epitope  (40).  Thus,  the  set  of anti-idiotope antibodies and  anti-epitope 
antibodies would be the same set. This concept, in its extreme form, is tenable only if 
the  expressed  idiotopes  of  Ig  cross-react  with  virtually  every  possible  antigenic 
determinant, including polysaccharides, lipids, and simple organic haptens. We regard 
this as quite unlikely in chemical terms. A second finding not well explained by linear 
or expanding idiotope-anti-idiotope chains is the capacity of Ab4 to bind Abl. 
We wish to propose a  very different idea to explain idiotope-anti-idiotope interac- 
tions (Fig. 5). In our model, the set ofanti-epitopes (Abl) and anti-idiotopes (Ab2) are 
functionally  distinct.  Thus,  we  suggest  that,  although  antibodies  to  conventional 
antigenic determinants bear many idiotopes, only a  limited number of these idiotopes 
function in eliciting responses in autologous or syngeneic animals. We designate such 
determinants "regulatory idiotopes." Thus,  the anti-idiotope antibodies that develop 
in autologous or syngeneic systems will be directed to a  limited number of determi- 
nants.  It should  be obvious that  Ab2 idiotopes will be similar to each other in  that 
each  binds  the  Abl  Id.  They  may  be  sufficiently heterogeneous  to  display a  large 
number  of regulatory idiotopes, each expressed on only a  small fraction of the Abz 
molecules. Alternatively, the set of Abe may differ from the set of Abl in that it fails 
to express regulatory idiotopes. In either case,  intentional or natural  immunization 
with Ab2 will be relatively efficient in activating those B cells that bear the regulatory 
aAb  3 
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Fio.  5.  The regulatory  idiotope concept.  Abl of the a  type (a Abl)  represents an anti-epitope 
antibody which possesses a regulatory  idiotope  (the a Abl idiotope). Immunization  of syngeneic 
animals with a Abl causes the production of the complementary anti-idiotope  antibody a Ab2,  which 
displays any of its individual idiotopes at low concentration  or because a Abz lacks a regulatory 
idiotope. Immunization of syngeneic mice with a Ab2 activates B lymphocytes that bear receptors 
that express the a Abl idiotope or related idiotopes (i.e., a Abl', a Abe"...a Abl"). Because a Ab2 
lacks a regulatory  idiotope, immunization  with it fails to cause activation  of anti-(anti-idiotope) 
antibodies. Thus, a Abz is really the collection of molecules that bear the a Abl and related idiotopes. 
Immunization with a Ab3 thus elicits the production  of antibodies specific for the a Abl family of 
regulatory idiotopes. Thus, a Ab2 and a Ab4 will resemble each other. The a Abl-a Ab2 system is one 
of a series of distinct complementary systems which include the b Abt-b Ab2, c Abl-c Ab2, ... z Abt- 
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idiotopes  for which  Ab2  is  specific  (the Abl  regulatory Id),  but  will  cause limited 
induction of anti-Abz, either because no single Ab2 Id is present at sufficiently high 
concentration to stimulate anti-Id antibodies, or because Ab2 molecules do not display 
regulatory  Id.  Therefore, for purposes  of immunization,  Ab2  functions  mainly  as 
an anti-Id  antibody rather than  as an  antigen.  The antibodies raised against  Ab2 
should resemble each other in that each will express the Abl regulatory idiotope or 
determinants that cross-react with this idiotope. We suggest that the number of such 
idiotopes  is  relatively small  and  that  antibodies  of very different specificities may 
share cross-reactive regulatory idiotopes. Thus, Ab3 should more correctly be regarded 
as  a  collection of molecules possessing  the  Abl-type regulatory idiotope  (i.e., Abl, 
Abl' ...  Abln), of which Abl will be only one member of a  relatively large family. 
Thus, the antigen-binding activity of Ab3 might be difficult to detect. On the other 
hand, immunization with antigen (e.g., BL) should reveal that Abl-bearing epitope- 
specific precursors have been "primed" by Ab2 immunization. That is, Abl should be 
represented  in  the  anti-epitope  response  to  a  larger  extent  than  in  animals  not 
immunized with Ab2. When Aba antibodies are used in immunization, the resultant 
Ab4 should bind Abl because Abl and Aba express cross-reactive regulatory idiotopes. 
Thus,  Ab4  should  be  similar  to  Aba,  because  both  are  directed  against  the  Aba 
regulatory idiotope. 
This model is consistent with several findings that have been reported previously. 
First, the concept that in syngeneic immunizations only the regulatory idiotopes are 
antigenic is consistent with the Lieberman-Potter rule (42). This states that it is much 
more  difficult  to  produce  anti-Id  antibodies  against  myeloma  proteins  when  the 
mouse immunized is of the same Igh-C type as the donor of the myeloma protein than 
when the immunized animal and the donor are of different lgh-C types. Second, the 
concept that Aba consist of molecules bearing idiotopes cross-reactive with Abl but 
that the serum of Ab3 mice has little antigen (e.g., BL)-binding activity is consistent 
with  reports  that  Id,  such  as  the  A5AId,  may be  found on  molecules capable  of 
binding a  given antigen  (e.g., Streptococcus A  carbohydrate), as well as molecules 
that have no detectable capacity to bind that antigen (43). 
Obviously, a  model of this sort  is  best  stated  in  extreme terms both  for ease of 
description  and  precision  of predictions.  Nonetheless,  one  must  consider  certain 
problems. First, Ab4 binds Ab3 with much higher affinity than it binds Abl. Thus, the 
Aba family (i.e., those molecules that bear regulatory idiotopes cross-reactive with that 
of Abl)  must be moderately heterogeneous. For simplicity, one would prefer a  very 
limited degree of heterogeneity in the Abl idiotope. However, this heterogeneity might 
be explained  by influences on  the conformation of the regulatory idiotope by the 
structure of other portions of the  hypervariable regions.  Second, we  demonstrated 
that Abl could inhibit the binding of 60-70% of radioactive Ab3 to Ab4 plates. This 
suggests that a  fraction of the Abn molecules may lack the Abl regulatory idiotopes, 
and that immunization with Ab2 actually elicits some anti-Ab2 antibodies. However, 
it should be pointed out that the immunization scheme, involving Ab2-KLH conju- 
gates, is not physiologic and may allow responses to idiotopes not normally immu- 
nogenic in spontaneous autoimmunization. 
Finally, one might speculate about whether regulatory idiotopes are a feature of all 
anti-epitope  antihodies  (i.e.,  all  Abl)  or  only  of a  subset  of Abl.  In  particular, 
regulatory idiotopes might be a  feature only of those Abl idiotopes that are capable 964  AUTO Abs AND SILENT CLONES 
of becoming dominant Id, possibly because it is these determinants that call forth Id- 
specific T  cell regulatory responses, as well as anti-idiotope (Ab2) antibodies. Indeed, 
Abl  bearing  anti-BL  antibodies  appear  to  be  under  the  regulatory control  of T 
lymphocytes because their expression in the anti-BL response of nu/nu BALB/c mice, 
pretreated with antibody to the IdX of anti-In, is inhibited by T  lymphocytes. Thus, 
if the  number  of distinct  regulatory idiotopes  is  relatively small,  the  existence of 
relatively large clones of regulatory T  lymphocytes specific for these idiotopes might 
explain the powerful effects of Id-determined T  lymphocyte regulation which have 
been increasingly observed in recent years. 
Finally, this anti-epitope-anti-idiotope concept or, more simply, this +,-  concept 
of the  Id-anti-Id regulatory system does have some network features in  that  many 
apparently unrelated Abt  idiotopes can be affected by the action of a  single Ab2. 
However, in the model we propose, the effect of a  single Abx-Ab2  system (i.e., the a 
Abl-a  Ab~  system)  should  be  limited  to  the  Abl  possessing  a  common  regulatory 
idiotope (the a Abl idiotope) and as such should be relatively isolated from other Abl- 
Ab2 systems (e.g., the b Abl-b Ab2, c Ahl-c Ab2,  . . .z Abl-z Ab2 systems) (Fig. 5). One 
might describe this system as a  "ping-pong" effect, in which the Abx side has many 
players and the Ab2 side has few. 
Summary 
BALB/c mice immunized multiple times with ABPC48  (A48 or Abl), a  BALB/c 
bacterial levan  (BL)-binding myeloma protein, produce anti-Abl  antibodies  (Ab2). 
Immunization  with  only two  doses  of Aba  often  leads  to  the  production  of anti- 
(antiA48)  (Abs)  as does immunization with hemocyanin conjugates of Ab2.  Finally, 
immunization with hemocyanin conjugates of Ab3 leads to the production of anti- 
(anti-[anti-A48])  (Ab4). Normal BALB/c mice immunized with BL produce an anti- 
BL antibody response containing no detectable Abt idiotype (Id)-bearing molecules. 
Mice producing Ab3 express substantial amounts of Abl Id in their anti-BL response 
whereas mice producing Ab2 and Ab4 show a generalized inhibition in their anti-BL 
response.  These results  indicate that  states of immunity within  an  idiotypic chain 
may have marked effects on antibody responses to the antigen (i.e.,  BL) which is the 
putative initiator of the chain. Strikingly, the chain itself has an interesting feature. 
That is, Aba and Aba share a cross-reactive Id in that both are bound by Ab4 and Ab2. 
We propose a  model of Id-anti-Id systems to explain this unexpected result. This is 
based  on the concept of regulatory idiotopes on  Abl  molecules which  initiate Ab2 
(anti-idiotope) responses. In contrast, Ab2 molecules generally fail to initiate anti-Abz 
Id responses either because any individual idiotope is present at very low concentration 
or because  Ab2  molecules  tend  to  lack  regulatory  idiotopes.  Thus,  Ab2  molecules 
immunize syngeneic animals because they interact with cells bearing Ab1-1ike regu- 
latory idiotopes. Thus, Aba will share regulatory idiotopes with Aba. Ab4 and Ab2 will 
share the ability to bind the Abl-like regulatory idiotope. 
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